Clinical Outcome and Prognostic Factors in 100 Cases of Uterine Sarcoma: Experience in Helsinki University Central Hospital 1990–2001

Koivisto-Korander, Riitta; Bützow, Ralf; Koivisto, Anna‐Maija; Leminen, Arto

doi:10.1097/01.ogx.0000340772.16228.30

Cited by 23 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data were consistent with Benito et al study which found CS in 48% and LMS in 22% (Benito et al, 2009). Contrast with other studies in Thailand, most common type are LMS .Other previous studies reported different findings, with similar frequency of CS and LMS (Kelly and Craighead, 2005;Koivisto et al, 2008;Park et al, 2008;Durnali et al, 2012). The small number of cases in each study might have exaggerated the different proportion of each uterine sarcoma type.…”

Section: Discussioncontrasting

confidence: 50%

“…The small number of cases in each study might have exaggerated the different proportion of each uterine sarcoma type. Nevertheless, our study and all other previous studies found ESS or AS as the least common constituting only 10-30% (Kelly and Craighead, 2005;Koivisto et al, 2008;Park et al, 2008;Benito et al, 2009;Durnali et al, 2012). Our patients' mean age of 54 years was within the range of 50 to 62 years reported in other studies (Livi et al, 2003;Park et al, 2008).…”

Section: Discussionmentioning

confidence: 50%

“…Their prognoses remained unchanged: overall 5-year survival ranged from 18% to 55% (Kelly and Craighead, 2005;Koivisto et al, 2008;Park et al, 2008;Durnali et al, 2012). Being rare tumors, large prospective studies or randomized controlled trials of uterine sarcoma are 1760 not common.…”

Section: Uterine Sarcoma: Clinical Presentation Treatment and Survivmentioning

confidence: 99%

See 2 more Smart Citations

Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand

Potikul¹,

Tangjitgamol²,

Khunnarong³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Uterine sarcoma is a group of rare gynecologic tumors with various natures, and different lines of treatment. Most have a poor treatment outcome. This study targeted clinical characteristics, treatment, overall survival (OS), progression-free survival (PFS), and prognostic factors in uterine sarcoma patients in one tertiary center for cancer care. Materials and Methods: Uterine sarcoma patients who were treated at the Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital between January 1994 and December 2014 were identified. Clinico-pathological data were analyzed. Prognostic outcomes were examined by Kaplan-Meier curves and Cox regression analysis. Results: We identified 46 uterine sarcoma patients: 25 carcinosarcoma (CS) (54.3%), 15 leiomyosarcoma (LMS) (32.6%), and 6 undifferentiated uterine sarcoma (UUS) (13.1%) cases. Mean age was 54.0±11.9 years (range 25-82 years). Abnormal uterine bleeding was the most common presenting symptom (63.0%). Among 33 patients (71.7%) who had pre-operative tissue collected, diagnosis of malignancy was correct in 29 (87.9%). All patients received primary surgery and retroperitoneal lymph nodes were resected in 34 (73.9%). After surgery, 5 (10.9%) had gross residual tumors. Stage I disease was most commonly found (56.5%). Adjuvant treatment was given to 27 (58.7%), most commonly chemotherapy. After a median follow-up of 16.0 months (range 0.8-187.4 months), recurrence was encountered in 22 patients (47.8%). Median time to recurrence was 5.8 months (range1.0-105.5 months). Distant metastasis was more common than local or locoregional failure. The 2-year PFS was 45.2% (95% confidence interval [CI], 30.6%-59.7%) and the 2-year OS was 48.3% (95% CI, 33.3%-60.7%). Multivariable analyses found residual disease after surgery as a significant factor only for PFS. Conclusions: Uterine sarcoma is a rare tumor entity. Even with multimodalities of treatment, the prognosis is still poor. Successful cytoreductive surgery is a key factor for a good survival outcome.Keywords: Uterine sarcoma -clinical characteristics -survival -prognostic factors -Thailand RESEARCH ARTICLE Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in ThailandChalermrat Potikul, Siriwan Tangjitgamol*, Jakkapan Khunnarong, Sunamchok Srijaipracharoen, Thaovalai Thavaramara, Kamol Pataradool the mainstay of treatment (Prat, 2009). Slightly different from its carcinoma counterpart, ovarian preservation and exemption of lymph node resection are sometimes acceptable particular in younger age patients and in those with certain types of sarcoma (Leitao et al., 2003;Kapp et al., 2008). Adjuvant therapy after surgery has evolved over the years without a clear benefit on survival (Cearbhail and Hensley, 2010;Rauh-Hain and Carmen, 2013;Cantrell et al., 2015).Despite being derived from various cellular origins and having different pathologic features, most sarcomas have aggressive behavior, high rates of recurrence and poor prognosis even when diagnosed at an early st...

show abstract

Section: Discussioncontrasting

confidence: 50%

Section: Discussionmentioning

confidence: 50%

See 1 more Smart Citation

Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand

Potikul¹,

Tangjitgamol²,

Khunnarong³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Our three patients had personal history of other malignancies, Benito et al and Koivisto-Korander et al have been reported higher occurence of previous cancer in this group of patients (Koivisto-Korander et al, 2008;Benito et al, 2009). Patients in MMMT group were mostly postmenopousal (88%), whereas rate of postmenapousal patients in LMS and ESS group were lower (45.1% and 22.2% respectively).…”

Section: Discussionmentioning

confidence: 86%

Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey

Durnalı¹,

Tokluoğlu²,

Özdemir³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Median overall survival (OS) was 56 months (95% CI, 22.5-89.5 months), and OS after 1, 2, 5 years was 84.7%, 78%, 49.4% respectively. Multivariate analysis showed that age ≥60 years and high grade tumor were significantly associated with poor OS and RFS; patients administered adjuvant treatment with sequential chemotherapy and radiotherapy had longer RFS time. Among patients with leiomyosarcoma, in addition to age and grade, adjuvant treatment with sequential chemotherapy and radiotherapy after surgery had significant effects on OS. Conclusion: Uterine sarcomas have poor progrosis even at early stages. Prognostic factors affecting OS were found to be age and grade.

show abstract

“…Depending on the histological classification used, uterine sarcomas represent about 3 to 9% of cancers of the corpus uteri and 1% of all cancers of the female reproductive system [19,21]. The prognosis for certain histological types, such as uterine sarcoma, is quite poor; overall 5-year survival ranges from 17 to 53% [21][22][23]. For endometrial stromal sarcoma, the www.e-shaw.org prognosis is better than for other uterine sarcomas.…”

Section: Endometrial Cancermentioning

confidence: 99%

Malignant Tumors of the Female Reproductive System

Weiderpass

Labrèche

2014

Occupational Cancers

View full text Add to dashboard Cite

This review summarizes the epidemiology of cancer of the female reproductive system and associated lifestyle factors. It also assesses the available evidence for occupational factors associated with these cancers. Cervical, endometrial, and ovarian cancers are relatively common, and cause significant cancer morbidity and mortality worldwide, whereas vulvar, vaginal, fallopian tube cancers, and choriocarcinomas are very rare. As several lifestyle factors are known to play a major role in the etiology of these cancers, very few published studies have investigated possible relationships with occupational factors. Some occupational exposures have been associated with increased risks of these cancers, but apart from the available evidence on the relationships between asbestos fibers and ovarian cancer, and tetrachloroethylene and cervical cancer, the data is rather scarce. Given the multifactorial nature of cancers of the female reproductive system, it is of the utmost importance to conduct occupational studies that will gather detailed data on potential individual confounding factors, in particular reproductive history and other factors that influence the body's hormonal environment, together with information on socio-economic status and lifestyle factors, including physical activity from multiple sources. Studies on the mechanisms of carcinogenesis in the female reproductive organs are also needed in order to elucidate the possible role of chemical exposures in the development of these cancers.

show abstract

Clinical Outcome and Prognostic Factors in 100 Cases of Uterine Sarcoma: Experience in Helsinki University Central Hospital 1990–2001

Cited by 23 publications

References 0 publications

Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand

Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand

Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey

Malignant Tumors of the Female Reproductive System

Contact Info

Product

Resources

About